Federal Drug Administration Related Press Releases

Many relevant press releases are published on PodiaPaedia 2018, (2017, 2016, 2015). Listed below are the press releases that are relevant to the topic of the Federal Drug Administration (FDA) in the USA.

13 Jul 2017: FDA Approves Tremfya

7 Jul 2017: FDA approves new treatment for sickle cell disease

6 Jul 2017: Bristol-Myers Squibb’s ORENCIA (abatacept) Receives FDA Approval for Treatment of Active Psoriatic Arthritis (PsA) in Adults

19 June 2017: FDA Approves Baxdela

16 June 2017: Ipsen Announces FDA approval of Dysport (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Adults

15 June 2017: FDA Approves Symjepi

22 May 2017: FDA approves first drug to specifically treat giant cell arteritis

18 May 2017: FDA-approved drug helps treat rare immunologic disease, study finds

3 Apr 2017: Teva Announces FDA Approval of AUSTEDO™ (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington’s Disease

30 Mar 2017: U.S. FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie’s HUMIRA® (adalimumab)

09 Feb 2017: FDA approves drug to treat Duchenne muscular dystrophy

05 Feb 2017: BioElectronics Corporation Announces US FDA OTC Clearances For Drug-free ActiPatch® Musculoskeletal Pain Therapy

19 Sep 2016: FDA Approves Exondys 51 (eteplirsen) for Duchenne Muscular Dystrophy

19 May 2016: FDA warns that prescribing of Nizoral (ketoconazole) oral tablets for unapproved uses including skin and nail infections continues

15 May 2015: FDA approves Zurampic to treat high blood uric acid levels associated with gout

Please contact us if we have missed any press releases or to forward a press release to us.

Other Collections of Press Releases:

Muscular Dystrophy	Brooks	Diabetes	Gout	Psoriasis
ASICS	Concussion	Antibiotic Resistance	The Marathon	Melanoma
Parkinson's	Alzheimer’s	Vitamin D	Plantar fasciitis	FDA
Autism	Multiple Sclerosis	Rheumatoid Arthritis	Obesity